MedTrace Logo

Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation

NCT02084160 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 579

Last updated 2022-12-20

Study results available
· View outcomes & findings →

Summary

The objectives of this study are:

* To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic decompensation events
* To evaluate the relationship between liver Biopsy and clinical outcome and show that the MBT has a better predictive ability of clinical outcome than liver biopsy.
* To evaluate the ability of the MBT to predict each of the individual liver related complications.

Conditions

Sponsors & Collaborators

  • Meridian Bioscience, Inc.

    lead INDUSTRY

Principal Investigators

  • Taufick Chori, MD · Hadassah Medical Organization

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2018-10-31
Completion
2018-11-30

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02084160 on ClinicalTrials.gov